Congenica
3 known investors
Congenica offers an AI-powered next-generation sequencing platform that turns raw genomic sequencing data into clinical insights across rare disease, oncology, and infectious diseases, along with clinical interpretation services staffed by NHS-trained genomic experts. It serves laboratories, clinicians, and national genomics programs, and is used by labs in over 35 countries.
AI & Machine LearningBiotechDigital Health
Investors · 3
Companies House · registry record
View on Companies House ↗- Registered name
- CONGENICA LTD
- Company number
- 08273616
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 30 Oct 2012
- Registered office
- Bic Wellcome Genome Campus, Hinxton, Cambridge, CB10 1DR
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 31 Dec 2024 · next due 30 Sept 2026
- Confirmation statement
- last made up to 30 Oct 2025 · next due 13 Nov 2026
Current officers · 3
- Pramex International Ltd — corporate secretary, appointed 16 Dec 2025
- Martin Dubuc — director, appointed 1 Sept 2025
- Alexander Kurze — director, appointed 28 Nov 2025
Source: Companies House public register · retrieved 16 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Congenica do?
- Congenica offers an AI-powered next-generation sequencing platform that turns raw genomic sequencing data into clinical insights across rare disease, oncology, and infectious diseases, along with clinical interpretation services staffed by NHS-trained genomic experts. It serves laboratories, clinicians, and national genomics programs, and is used by labs in over 35 countries.
- Who are Congenica's investors?
- Congenica's investors include QVentures, Cambridge Innovation Capital, Future Planet Capital.